| Literature DB >> 35209210 |
Zainab H Abdul-Hameed1, Nahed O Bawakid1, Hajer S Alorfi1, Tariq R Sobahi1, Najla Ali Alburae2, Ahmed Abdel-Lateff3,4, Serag Eldin I Elbehairi5,6, Mohammad Y Alfaifi5, Nabil A Alhakamy7, Walied M Alarif8.
Abstract
Chromatographic investigation of the aerial parts of the Rhazya stricta (Apocynaceae) resulted in the isolation of two new monoterpene indole alkaloids, 6-nor-antirhine-N1-methyl (1) and razyamide (2), along with six known compounds, eburenine (3), epi-rhazyaminine (4), rhazizine (5), 20-epi-sitsirikine (6), antirhine (7), and 16-epi-stemmadenine-N-oxide (8). The chemical structures were established by various spectroscopic experiments. Compounds 1-8 exhibited cytotoxic effects against three cancer cells with IC50 values ranging between 5.1 ± 0.10 and 93.2 ± 9.73 µM against MCF-7; 5.1 ± 0.28 and 290.2 ± 7.50 µM against HepG2, and 3.1 ± 0.17 and 55.7 ± 4.29 µM against HeLa cells. Compound 2 showed the most potent cytotoxic effect against all cancer cell lines (MCF-7, HepG2 and HeLa with IC50 values = 5.1 ± 0.10, 5.1 ± 0.28, and 3.1 ± 0.17 µM, respectively). Furthermore, compound 2 revealed a significant increase in the apoptotic cell population of MCF-7, HepG2, and HeLa cells, with 31.4 ± 0.2%, 29.2 ± 0.5%, and 34.9 ± 0.6%, respectively. Compound 2 decreased the percentage of the phagocytic pathway on HepG2 cells by 15.0 ± 0.1%. These findings can explain the antiproliferative effect of compound 2.Entities:
Keywords: Apocynaceae; HeLa; HepG2; MCF-7; Saudi plants; alkaloids; cytotoxicity
Mesh:
Substances:
Year: 2022 PMID: 35209210 PMCID: PMC8878105 DOI: 10.3390/molecules27041422
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Compounds isolated from the aerial parts of Rhazya stricta.
1H, 13C-NMR and HMBC of compound 1 a.
| Position | δC b | δH c | HMBC |
|---|---|---|---|
| 2 | 137.1 s | - | 11, 9 |
| 3 | 55.6 d | 4.08 brs | 19, 5a |
| 5a | 52.7 t | 3.16 dd (9.0, 4.8) | |
| 7 | 107.5 s | - | 9, 5a |
| 8 | 128.3 s | - | 9, 10, 12 |
| 9 | 118.3 d | 7.38 d (7.8) | 11, 12 |
| 10 | 119.4 d | 6.96 ddd (7.8, 7.8, 1.2) | 12 |
| 11 | 121.4 d | 7.01 ddd (7.8, 7.8, 1.2) | 9 |
| 12 | 111.8 d | 7.30 d (7.8) | 10 |
| 13 | 137.3 s | - | 9, 11, Me |
| 14a | 32.1 t | 2.14 m | |
| 15 | 32.0 d | 1.66 m | |
| 16a | 28.6 t | 1.70 ddd (16.8, 9.0, 4.2) | Me |
| 17a | 48.5 t | 2.77 m | |
| 17b | 2.68 m | ||
| 18a | 116.8 t | 5.05 d (1.8) | |
| 19 | 140.5 d | 5.69 ddd (18.6, 12.0, 9.6) | 18a, 18b, 21a, 21b |
| 20 | 49.6 d | 2.28 brs | 18a, 18b, 19 |
| 21a | 63.9 t | 3.66 dd (10.8, 6.0) | 19 |
| N-CH3 | 49.6 s | 3.29 |
aAll assignments are based on 1D and 2D measurements (HMBC, HSQC, COESY). b Implied multiplicities were determined by DEPT (C = s, CH = d, CH2 = t). c J in Hz.
1H, 13C-NMR, and HMBC of compound 2 a.
| Position | δC b | δH c | HMBC |
|---|---|---|---|
| 2 | 133.0 s | - | |
| 3 | 27.7 d | 4.45 d (7.6) | 7 |
| 5a | 50.3 t | 3.17 dd (11.0,4.5) | 6,7,21 |
| 6a | 20.3 t | 3.03 m | 2, 7 |
| 7 | 107.8 s | - | |
| 8 | 126.3 s | - | |
| 9 | 118.1 d | 7.45 d (7.6) | 7,8,11,12,13 |
| 10 | 119.5 d | 7.08 dd (7.6,7.6) | 8,9,11,12,13 |
| 11 | 121.9 d | 7.12 dd (7.6,7.6) | 8,9,12,13,2 |
| 12 | 111.1 d | 7.28 d (7.6) | 7,8,10 |
| 13 | 136.6 s | - | |
| 14a | 33.6 t | 2.64 br.s | 2,7,16, OMe |
| 15 | 53.7 d | 3.82 brs | 16, OMe |
| 16 | 170.7 s | - | |
| 17 | 168.4 s | - | |
| 18 | 13.1 q | 1.79 brs | 19,20 |
| 19 | 121.9 d | 5.38 q (6.8) | 3,18,20,21 |
| 20 | 133.0 s | - | |
| 21a | 59.0 t | 3.91 d (13.6) | 6,7,15,20 |
| OCH3 | 51.2 t | 3.69 s | 16,7 |
| NH | - | 7.92 s | 3,7,16,20 |
a All assignments are based on 1D and 2D measurements (HMBC, HSQC, COESY). b Implied multiplicities were determined by DEPT (C = s, CH = d, CH2 = t). c J in Hz.
Cytotoxic effects of compounds 1–8 isolated from Rhazya stricta.
| Compound No. | IC50 (µM) | ||
|---|---|---|---|
| MCF-7 | HepG2 | HeLa | |
| 1 | 68.9 ± 3.45 | 52.7 * ± 2.02 | 30.7 * † ± 2.67 |
| 2 | 5.1 ± 0.10 | 5.1 ± 0.28 | 3.1 * † ± 0.17 |
| 3 | 50.7 ± 2.29 | 40.0 * ± 3.40 | 55.7 * † ± 4.29 |
| 4 | 40.5 ± 1.89 | 290.2 * ± 7.50 | 23.4 * † ± 2.07 |
| 5 | 93.2 ± 9.73 | 118.8 * ± 8.48 | 36.9 * † ± 2.18 |
| 6 | 52.2 ± 2.60 | 21.1 * ± 1.97 | 12.4 * † ± 1.51 |
| 7 | 65.4 ± 3.67 | 60.7 ± 3.30 | 23.2 * † ± 1.68 |
| 8 | 50.0 ± 2.31 | 54.9 ± 2.00 | 32.8 * † ± 2. 70 |
| Doxorubicin | 1.96 ± 0.02 | 1.8 ± 0.01 | 3.1 * † ± 0.15 |
Human mammary gland, breast adenocarcinoma (MCF-7), hepatocellular carcinoma (HepG2), and human cervix adenocarcinoma (HeLa). Data are presented as the mean ± SD; n = 3. * Significantly different from corresponding MCF-7 value, † Significantly different from corresponding HepG2 value.
Figure 2Effect of compound 2 on cell cycle phases of MCF-7, HepG2 and HeLa cells. Cell cycle distribution was determined using DNA cytometry analysis after exposure to 2 for 48 h. Data are presented as the mean ± SD; n = 3; ** p < 0.01 and *** p < 0.001.
Figure 3Apoptosis/necrosis assessment for compound 2 against MCF-7, HepG2, and HeLa cells subjected to previous treatment for 48 h, and apoptosis/necrosis quantified using flow cytometry. Data are presented as the mean ± SD; n = 3; ** p < 0.01 and *** p < 0.001.
Figure 4Effect of compound 2 on the autophagy cell death in MCF-7, HepG2, and HeLa cells. Exposure to treatments for 48 h. Data are presented as the mean ± SD; n = 3; * p < 0.05, ** p < 0.01.